Adrenal Insufficiency: Review of Clinical Outcomes With Current Glucocorticoid Replacement Therapy Gudmundur Johannsson, Alberto Falorni, Stanko Skrtic, Hans Lennernäs, Marcus Quinkler, John P. Monson, Paul M.Stewart Disclosures Clin Endocrinol. 2015;82(1):2-11. Glucocorticoid replacement therapy in patients with adrenal insufficiency (AI), whether primary (Addison's disease) or secondary (due to hypopituitarism), has been established for some 50 years.
The current standard treatment regimen involves twice- or thrice-daily dosing with a glucocorticoid, most commonly oral hydrocortisone. Based on previous small-scale studies and clinical perception, life expectancy with conventional glucocorticoid replacement therapy has been considered normal, with a low incidence of adverse events. Data from the past 10–15 years, however, have shown that morbidity remains high and life expectancy is…
